Developer docs
API playgroundTry for free, no card

Search company profiles

ALS Canada

Full company profile

uuid00ym212

Namestring
ALS Canada
Legal namestring
ALS Society of Canada
Websiteurl
als.ca
Company typeenum
Private
Founded yearint
1977
Descriptiontext

ALS Canada, legally known as the ALS Society of Canada, is a Toronto-based charitable nonprofit founded in 1977 that operates as the only national voluntary health organization in Canada dedicated to amyotrophic lateral sclerosis (ALS). The organization serves approximately 4,000 Canadians currently living with ALS, along with their families and caregivers, providing support services, advocacy, and research funding for a progressive neuromuscular disease with no cure and a 1-in-300 lifetime risk. Its core offerings are programmatic rather than productized: it distributes free educational content (e.g., the book 'Letters to ALS: Our Journeys to Hope'), coordinates assistive-technology resources, convenes patients and clinicians, and leads policy advocacy including on Parliament Hill for sustained federal research investment through initiatives such as the Canadian Collaboration to Cure ALS.

Its underlying operating model is grant- and donation-funded nonprofit advocacy and community organizing. The organization does not sell a defined product or service portfolio; its revenue mechanics are not publicly disclosed and pricing information is not available. Distribution occurs through online channels, ALS clinics across Canada, and in-person professional forums (including the December 2025 Annual Meeting and Allied Professionals Forum in Toronto, which drew over 300 health professionals, caregivers, and patients). It maintains partnerships with the International Alliance of ALS/MND Associations, the U.S.-based ALS Association, the Canadian Collaboration to Cure ALS coalition, and corporate sponsors such as Tanabe Pharma Canada for content co-production. In 2025, Health Canada approved Qalsody (tofersen) for SOD1-ALS, a regulatory milestone the organization cites as evidence that ALS can be treatable when research is prioritized.

The organization has no disclosed technology platform, software products, AI/ML capabilities, or paid customer base. Its competitive position rests on its unique national mandate, four-decade operating history, established relationships with clinicians and policymakers, and its convening role across the Canadian ALS community. There is no headcount, no parent or subsidiary structure, and no disclosed financial data in the source material.

Short descriptiontext

ALS Canada (ALS Society of Canada) is a Toronto-based nonprofit founded in 1977 that serves approximately 4,000 Canadians living with ALS through patient support, advocacy, and research funding as the only national voluntary health organization dedicated to the disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
ALS patient support, neuromuscular disease advocacy, nonprofit health organization, disease research funding, patient advocacy services
Industry3 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGALAM
Disability Services & Assistive Solutions (Accessibility, Assistive Tech)
Business & Public Services/Nonprofit, NGO & Social Services/Social Enterprises & Impact Organizations
SECONDARYBPAGAFAF
Disability Rights & Accessibility Advocacy
Business & Public Services/Nonprofit, NGO & Social Services/Civil Rights, Advocacy & Public Policy Organizations
NAICS code3 codes
  • Voluntary Health Organizations813212
  • Social Advocacy Organizations8133
  • Grantmaking and Giving Services81321
SIC code2 codes
  • Services-Membership Organizations8600
  • Services-Social Services8300
Product category
Neuromuscular Disease Nonprofit Support Services
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

ALS Canada (ALS Society of Canada) is a national charitable nonprofit organization that supports Canadians affected by amyotrophic lateral sclerosis (ALS) through patient and family support services, advocacy for policy and research funding, and funding of ALS research initiatives. It connects approximately 4,000 Canadians living with ALS with clinicians, researchers, and advocates through programs, professional forums, and free educational resources.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Based on the source data, ALS Canada (referenced as ALS Society of Canada) is a charitable organization focused on ALS (amyotrophic lateral sclerosis) research advocacy, awareness, and community support. The available source material does not provide specific information about a product or service portfolio beyond general organizational activities including research funding, advocacy efforts, and community support programs. Note: A separate entity called "ALS Canada Ltd." is as a laboratory assay service provider, but this appears to be a distinct mineral analysis laboratory company rather than the same organization.

Product and service3 records
1Patient and Family Support Services
CategoryPatient Support Services
Description

Free support services for individuals living with ALS and their families, addressing emotional distress, community connection, and access to disease information and resources.

2ALS Research Advocacy and Policy Engagement
CategoryAdvocacy Services
Description

Advocacy and policy engagement to drive sustained government and stakeholder investment in ALS research, awareness, and treatment access in Canada.

3ALS Research Funding Program
CategoryResearch Funding
Description

Grant-making program that funds ALS research initiatives aimed at understanding, treating, and ultimately curing amyotrophic lateral sclerosis.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-03-26
Description

Tanabe Pharma Canada collaborated with ALS patient organizations across Canada to publish 'Letters to ALS: Our Journeys to Hope,' a book sponsored by Tanabe Pharma Canada as part of their long-standing commitment to the ALS community. The book is available free of charge online and in limited printed copies through ALS clinics and advocacy organizations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

The International Alliance of ALS/MND Associations held its Annual Meeting and Allied Professionals Forum in early December 2025 in Toronto, co-hosted by ALS Society of Canada and the ALS Association. This partnership brings together over 300 health professionals, caregivers, and people living with ALS to explore assistive technologies and share knowledge.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

The ALS Association partnered with ALS Society of Canada to co-host the Annual Meeting and Allied Professionals Forum in Toronto in December 2025. This cross-border collaboration represents a major international partnership between the two leading ALS organizations in North America.

4Canadian Collaboration to Cure ALS
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

ALS Canada led advocacy efforts on Parliament Hill in fall 2025 to support the Canadian Collaboration to Cure ALS initiative, reinforcing the need for sustained investment in ALS research. This represents a flagship advocacy partnership for advancing cure-focused research initiatives.

financialpost.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The leading US-based ALS voluntary health organization and a current strategic partner of ALS Canada. Both organizations run parallel national programs in research funding, advocacy, and patient services, and are the most natural international peer for ALS Canada.

2MS Society of Canada
TypeBroad incumbent
Description

Larger Canadian voluntary health organization focused on multiple sclerosis. A comparable Canadian nonprofit in scale, structure, and research-funding/advocacy/service mix, but with a far larger addressable patient base. Useful as a structural benchmark.

TypeRegional player
Description

Canadian nonprofit serving a related neuromuscular disease population. Comparable in structure, Canadian scope, research-funding role, and patient-services mix, but with a broader disease portfolio that competes for the same neuromuscular-disease donor dollar.

TypeRegional player
Description

Quebec-focused ALS nonprofit providing services and funding research. A direct provincial peer to ALS Canada, offering an alternative channel for Canadian ALS donors and a potential partnership/merger candidate.

5Project ALS
TypeDirect peer
Description

US nonprofit funding ALS research and patient advocacy with a research-grant-led model. Closely comparable to ALS Canada in mission, research-funding focus, and reliance on high-net-worth and family-foundation donors.

TypeDirect peer
Description

US-based nonprofit biotech focused on pre-clinical ALS therapeutic development. Operates in the same disease space with a research-driven mandate comparable to ALS Canada's research-funding pillar.

TypeBroad incumbent
Description

Canadian nonprofit supporting people with Parkinson's disease. Operates a parallel model of research funding, advocacy, and patient services within the Canadian neurodegenerative-disease nonprofit space.

TypeBroad incumbent
Description

Canada's largest disease-focused voluntary health organization, providing research funding, advocacy, and patient support. Relevant as a structural and scale benchmark for ALS Canada's national nonprofit model.

TypeRegional player
Description

Chicago-based ALS-specific nonprofit offering patient services, research grants, and advocacy. Smaller in geography but otherwise a structurally direct peer in disease focus, service mix, and donor-driven nonprofit model.

TypeDirect peer
Description

Global federation of ALS/MND patient organizations. ALS Canada co-hosted the Alliance's 2025 Annual Meeting in Toronto, demonstrating operational equivalence and a deeply comparable mission, member base, and event-driven model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ALS Canada

Neuromuscular Disease Nonprofit Support Servicesals.ca

ALS Canada (ALS Society of Canada) is a Toronto-based nonprofit founded in 1977 that serves approximately 4,000 Canadians living with ALS through patient support, advocacy, and research funding as the only national voluntary health organization dedicated to the disease.

What ALS Canada does

ALS Canada, legally known as the ALS Society of Canada, is a Toronto-based charitable nonprofit founded in 1977 that operates as the only national voluntary health organization in Canada dedicated to amyotrophic lateral sclerosis (ALS). The organization serves approximately 4,000 Canadians currently living with ALS, along with their families and caregivers, providing support services, advocacy, and research funding for a progressive neuromuscular disease with no cure and a 1-in-300 lifetime risk. Its core offerings are programmatic rather than productized: it distributes free educational content (e.g., the book 'Letters to ALS: Our Journeys to Hope'), coordinates assistive-technology resources, convenes patients and clinicians, and leads policy advocacy including on Parliament Hill for sustained federal research investment through initiatives such as the Canadian Collaboration to Cure ALS.

Its underlying operating model is grant- and donation-funded nonprofit advocacy and community organizing. The organization does not sell a defined product or service portfolio; its revenue mechanics are not publicly disclosed and pricing information is not available. Distribution occurs through online channels, ALS clinics across Canada, and in-person professional forums (including the December 2025 Annual Meeting and Allied Professionals Forum in Toronto, which drew over 300 health professionals, caregivers, and patients). It maintains partnerships with the International Alliance of ALS/MND Associations, the U.S.-based ALS Association, the Canadian Collaboration to Cure ALS coalition, and corporate sponsors such as Tanabe Pharma Canada for content co-production. In 2025, Health Canada approved Qalsody (tofersen) for SOD1-ALS, a regulatory milestone the organization cites as evidence that ALS can be treatable when research is prioritized.

The organization has no disclosed technology platform, software products, AI/ML capabilities, or paid customer base. Its competitive position rests on its unique national mandate, four-decade operating history, established relationships with clinicians and policymakers, and its convening role across the Canadian ALS community. There is no headcount, no parent or subsidiary structure, and no disclosed financial data in the source material.

ALS Canada firmographics

Firmographics
Name
ALS Canada
Legal name
ALS Society of Canada
Website
https://als.ca
Company type
Private
Founded year
1977
Operating status
Operating
Headcount range
11–50 employees
Short description
ALS Canada (ALS Society of Canada) is a Toronto-based nonprofit founded in 1977 that serves approximately 4,000 Canadians living with ALS through patient support, advocacy, and research funding as the only national voluntary health organization dedicated to the disease.
Ownership category
akta.pro rank

ALS Canada industry classification

Industry
Product category
Neuromuscular Disease Nonprofit Support Services
NAICS
Voluntary Health Organizations (813212), Social Advocacy Organizations (8133), Grantmaking and Giving Services (81321)
SIC
Services-Membership Organizations (8600), Services-Social Services (8300)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGALAM
Disability Services & Assistive Solutions (Accessibility, Assistive Tech)
Business & Public Services/Nonprofit, NGO & Social Services/Social Enterprises & Impact Organizations
SECONDARYBPAGAFAF
Disability Rights & Accessibility Advocacy
Business & Public Services/Nonprofit, NGO & Social Services/Civil Rights, Advocacy & Public Policy Organizations

Keywords

  • ALS patient support
  • Neuromuscular disease advocacy
  • Nonprofit health organization
  • Disease research funding
  • Patient advocacy services

Where ALS Canada is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Markets served

ALS Canada business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Distribution channels2 records

Marketing channels3 records

ALS Canada product offering

Product offering

Core offering

ALS Canada (ALS Society of Canada) is a national charitable nonprofit organization that supports Canadians affected by amyotrophic lateral sclerosis (ALS) through patient and family support services, advocacy for policy and research funding, and funding of ALS research initiatives. It connects approximately 4,000 Canadians living with ALS with clinicians, researchers, and advocates through programs, professional forums, and free educational resources.

Product overview

Based on the source data, ALS Canada (referenced as ALS Society of Canada) is a charitable organization focused on ALS (amyotrophic lateral sclerosis) research advocacy, awareness, and community support. The available source material does not provide specific information about a product or service portfolio beyond general organizational activities including research funding, advocacy efforts, and community support programs. Note: A separate entity called "ALS Canada Ltd." is as a laboratory assay service provider, but this appears to be a distinct mineral analysis laboratory company rather than the same organization.

Differentiator

Problem solved

Functional benefit

Products and services

  • Patient and Family Support Services Free support services for individuals living with ALS and their families, addressing emotional distress, community connection, and access to disease information and resources.
  • ALS Research Advocacy and Policy Engagement Advocacy and policy engagement to drive sustained government and stakeholder investment in ALS research, awareness, and treatment access in Canada.
  • ALS Research Funding Program Grant-making program that funds ALS research initiatives aimed at understanding, treating, and ultimately curing amyotrophic lateral sclerosis.

Companies that use ALS Canada

Customer profile

Segments1 record

Ideal customer profiles2 records

ALS Canada technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

ALS Canada partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Tanabe Pharma CanadaminorGTM or Marketing Partner · 26 March 2026Tanabe Pharma Canada collaborated with ALS patient organizations across Canada to publish 'Letters to ALS: Our Journeys to Hope,' a book sponsored by Tanabe Pharma Canada as part of their long-standing commitment to the ALS community. The book is available free of charge online and in limited printed copies through ALS clinics and advocacy organizations.
  • International Alliance of ALS/MND AssociationscoreStrategic or Co-development Partner · 1 December 2025The International Alliance of ALS/MND Associations held its Annual Meeting and Allied Professionals Forum in early December 2025 in Toronto, co-hosted by ALS Society of Canada and the ALS Association. This partnership brings together over 300 health professionals, caregivers, and people living with ALS to explore assistive technologies and share knowledge.
  • ALS AssociationcoreStrategic or Co-development Partner · 1 December 2025The ALS Association partnered with ALS Society of Canada to co-host the Annual Meeting and Allied Professionals Forum in Toronto in December 2025. This cross-border collaboration represents a major international partnership between the two leading ALS organizations in North America.
  • Canadian Collaboration to Cure ALScoreStrategic or Co-development Partner · 1 January 2025ALS Canada led advocacy efforts on Parliament Hill in fall 2025 to support the Canadian Collaboration to Cure ALS initiative, reinforcing the need for sustained investment in ALS research. This represents a flagship advocacy partnership for advancing cure-focused research initiatives.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

ALS Canada competitors and assessment

Company assessment

Direct peers

  • ALS Association: The leading US-based ALS voluntary health organization and a current strategic partner of ALS Canada. Both organizations run parallel national programs in research funding, advocacy, and patient services, and are the most natural international peer for ALS Canada.
  • Project ALS: US nonprofit funding ALS research and patient advocacy with a research-grant-led model. Closely comparable to ALS Canada in mission, research-funding focus, and reliance on high-net-worth and family-foundation donors.
  • ALS Therapy Development Institute: US-based nonprofit biotech focused on pre-clinical ALS therapeutic development. Operates in the same disease space with a research-driven mandate comparable to ALS Canada's research-funding pillar.
  • International Alliance of ALS/MND Associations: Global federation of ALS/MND patient organizations. ALS Canada co-hosted the Alliance's 2025 Annual Meeting in Toronto, demonstrating operational equivalence and a deeply comparable mission, member base, and event-driven model.

Broad incumbents

  • MS Society of Canada: Larger Canadian voluntary health organization focused on multiple sclerosis. A comparable Canadian nonprofit in scale, structure, and research-funding/advocacy/service mix, but with a far larger addressable patient base. Useful as a structural benchmark.
  • Parkinson Canada: Canadian nonprofit supporting people with Parkinson's disease. Operates a parallel model of research funding, advocacy, and patient services within the Canadian neurodegenerative-disease nonprofit space.
  • Canadian Cancer Society: Canada's largest disease-focused voluntary health organization, providing research funding, advocacy, and patient support. Relevant as a structural and scale benchmark for ALS Canada's national nonprofit model.

Regional players

  • Muscular Dystrophy Canada: Canadian nonprofit serving a related neuromuscular disease population. Comparable in structure, Canadian scope, research-funding role, and patient-services mix, but with a broader disease portfolio that competes for the same neuromuscular-disease donor dollar.
  • ALS Quebec (Société SLA du Québec): Quebec-focused ALS nonprofit providing services and funding research. A direct provincial peer to ALS Canada, offering an alternative channel for Canadian ALS donors and a potential partnership/merger candidate.
  • Les Turner ALS Foundation: Chicago-based ALS-specific nonprofit offering patient services, research grants, and advocacy. Smaller in geography but otherwise a structurally direct peer in disease focus, service mix, and donor-driven nonprofit model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

ALS Canada social profiles

Digital presence

ALS Canada financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ALS Canada leadership team

Management profile

Number of profiles

ALS Canada funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ALS Canada M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALS Canada

What does ALS Canada do?

ALS Canada (ALS Society of Canada) is a national charitable nonprofit organization that supports Canadians affected by amyotrophic lateral sclerosis (ALS) through patient and family support services, advocacy for policy and research funding, and funding of ALS research initiatives. It connects approximately 4,000 Canadians living with ALS with clinicians, researchers, and advocates through programs, professional forums, and free educational resources.

Is ALS Canada a public or private company?

ALS Canada is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was ALS Canada founded?

ALS Canada was founded in 1977. It employs 11 to 50 people.

Where is ALS Canada based?

ALS Canada is headquartered in Toronto, Canada, in the North America region.

Who are ALS Canada's main competitors?

Direct peers on record are ALS Association, Project ALS, ALS Therapy Development Institute and International Alliance of ALS/MND Associations. Broad incumbents are MS Society of Canada, Parkinson Canada and Canadian Cancer Society. Regional players are Muscular Dystrophy Canada, ALS Quebec (Société SLA du Québec) and Les Turner ALS Foundation.

Does ALS Canada have an API?

No public API is recorded for ALS Canada.

What industry is ALS Canada in?

ALS Canada's product category is Neuromuscular Disease Nonprofit Support Services. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPAGALAM, Disability Services & Assistive Solutions (Accessibility, Assistive Tech). Its NAICS code is 813212 and its SIC code is 8600.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialALS Canada Advances A National Strategy For ALS Genetics With Support From TDTD Bank Group renewed support for ALS Canada's national ALS genetics strategy, building on a 2024 $265,000 donation that created Canada's first ALS National Genetic Counsellor role. The renewed funding will advance genetic counselling, education, testing, and guidelines for Canadians affected by or at risk of ALS.GlobeNewswireAs defence spending rises, ALS community calls for greater federal investment in ALS researchThe ALS community in Canada is urging the federal government to invest $50 million over five years in ALS research, citing veterans' higher risk of the disease. The request targets nearly 4,000 Canadians living with ALS, with life expectancy of two to five years after diagnosis.Local Breaking‘Choices people should not have to make’: Financial burden of ALS pushing Canadian families to the brinkALS Canada released a study finding ALS costs $628.2 million annually in Canada, with families bearing 78% of the burden. The organization is urging a $50 million federal research investment over five years. No cure exists, and 80% of patients die within two to five years of diagnosis.Financial PostALS Canada rallies around progress in research and a call for continued action this ALS Awareness MonthDuring ALS Awareness Month, the ALS Society of Canada highlighted meaningful progress in amyotrophic lateral sclerosis research, including Health Canada's 2025 approval of Qalsody (tofersen) for SOD1-ALS, which demonstrated that ALS can be treatable when research is prioritized. ALS Canada also reinforced the need for sustained investment by recalling its advocacy efforts on Parliament Hill in fall 2025 for the Canadian Collaboration to Cure ALS initiative. The organization emphasized that despite this progress, ALS remains underfunded and under-recognized in Canada, urging continued public support.Stock TitanQuartz Mountain completes Phase 4 drilling at MaestroQuartz Mountain Resources Ltd. completed its Phase 4 core drilling program totaling 4,366 meters across 8 drill holes at the Maestro gold-silver project in central British Columbia, with all samples delivered to ALS Canada Ltd. for assay analysis. The company has $2.9 million in treasury and received a BC government drill permit for 37 additional sites, planning to mobilize Phase 5 drilling later in 2026. Chairman Bob Dickinson highlighted the discovery of three integrated mineral deposit types—epithermal gold-silver, porphyry gold, and porphyry copper-molybdenum—and noted the project's age dating compares favorably to the Blackwater Gold Mine.NewswireFinding Strength in Shared Stories: Tanabe Pharma Canada Introduces New Book for the Canadian ALS CommunityTanabe Pharma Canada announced the publication of Letters to ALS: Our Journeys to Hope, a book containing personal letters from people living with ALS, family members, clinicians, researchers, and advocates written directly to the disease. The book, developed in collaboration with ALS patient organizations across Canada and sponsored by Tanabe Pharma Canada as part of the company's long-standing commitment to the ALS community, is available free of charge online and in limited printed copies through ALS clinics and advocacy organizations. The initiative aims to deepen understanding of ALS, strengthen community connection, and provide emotional support to those affected by the disease, which affects approximately 4,000 Canadians with 80 percent of patients dying within two to five years of diagnosis.GlobeNewswireSunwing Vacations Facebook Campaign Raises $10,000 for ALS Canada in Less Than 24 HoursSunwing Vacations' Facebook campaign for the ALS Ice Bucket Challenge raised $10,000 for ALS Canada in under 24 hours. The campaign pledged $10 per share, reaching the goal in 11 hours. The company also donated $2,000 to its partner OneXOne.GlobeNewswireOne Plane. One Rope. One Great Cause.: 2013 Bombardier Plane Pull for ALS CanadaThe 2013 Bombardier Plane Pull for ALS Canada will take place in Toronto on Sunday, with 24 teams of 10 pulling a 37,000-lb Bombardier Q400 aircraft 100 meters. The event aims to raise awareness and funds for ALS Canada, supporting equipment, research, and patient services.